drugset
drugset / Trial / NCT05913037

FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas

NCT05913037 ↗

Phase 3 Active not recruiting 167 enrolled Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A study to evaluate the efficacy of FCN-159 in adult patients with symptomatic, inoperable neurofibromatosis type 1-related plexiform neurofibromas.

Timeline

Start
2023-06-20
Primary completion
2025-08-19
Completion
2026-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Luvometinib Small molecule 8 mg Oral

Indications

neurofibromatosis type 1 plexiform neurofibroma